Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Clinical trial NCT06590857 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06590857
Sponsor: RayzeBio, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer HER2-negative Breast Cancer ER+ Breast Cancer Advanced Breast Cancer

Start date: 2024-07-19
Primary completion: 2028-10-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.